The stage has officially been set for one of the largest biotech patent disputes to date. The stakes are high in this clash between scientific powerhouses: a potential Nobel Prize, the patent rights to a breakthrough gene-editing process, and (of course) a lot of money for the research institution involved.
This post was originally published on the Cardozo Arts & Entertainment Law Journal website on April 26, 2016. The original post can be accessed via the Archived Link button above.
Thalen, Katie, "The CRISPR-Cas9 Patent Dispute" (2016). AELJ Blog. 112.